Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 3/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7664249 | 0.71 | CRBN (0.36) | CRBNDDB1DUTCA12CA1 | |
| SCHEMBL31001871 | 0.69 | PLAT (0.50) | CRBNNPC1RAB9APDE3AHCAR1 | |
| SCHEMBL31001777 | 0.68 | CRBN (0.34) | CRBNDDB1NPC1RAB9AHCAR1 | |
| SCHEMBL7717839 | 0.68 | NPC1 (0.50) | CRBNNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL708133 | 0.67 | TDP1 (0.37) | CRBNDDB1PDE10A | |
| SCHEMBL6217559 | 0.67 | CRBN (0.41) | CRBNDDB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21929908 | 0.66 | CRBN (0.36) | CRBNDDB1NPC1RAB9APDE3A | |
| SCHEMBL23948426 | 0.65 | TDO2 (0.40) | NPC1HCAR1PDE9A | |
| SCHEMBL26683827 | 0.65 | CRBN (0.51) | CRBNDDB1DUTCA1CA4 | |
| SCHEMBL173531 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6379395-B1 | DYEING FOR HAIR DYE | L'OREAL S.A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-0888109-B1 | KERATIN FIBRE DYE COMPOSITION CONTAINING PYRAZOLO-PYRIMIDINEOXO COMPOUNDS, USE THEREOF AS DYE COUPLERS, AND DYEING METHODS | OREAL (FR) | 2000-08-30 | — | — | EP | claimed |
| JP-2214858-A | — | — | None | — | — | JP | disclosed |
| EP-4658655-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024160278-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| US-11485745-B2 | Amido spirocyclic amide and sulfonamide derivatives | VALO HEALTH, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | VALO HEALTH, INC. | 2021-06-10 | — | — | US | disclosed |
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008025822-A1 | DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-7262199-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| US-6379395-B1 | DYEING FOR HAIR DYE | L'OREAL S.A. (FR) | 2002-04-30 | — | — | US | disclosed |
| US-6179882-B1 | OXIDATION COLOR DYES | L'OREAL (FR) | 2001-01-30 | — | — | US | disclosed |
| JP-H02214858-A | NOVEL PHOTOGRAPHIC COLOR COUPLER AND SILVER HALIDE PHOTOGRAPHIC SENSITIVE MATERIAL CONTAINING THE SAME | FUJI PHOTO FILM CO LTD | 1990-08-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | STS, AADAC, SULT2A1 | CRBN 4530/4885DDB1 4362/4885NPC1 699/4885 |
| US-11485745-B2 | Amido spirocyclic amide and sulfonamide derivatives | STS, AADAC, SULT2A1 | CRBN 4530/4885DDB1 4362/4885NPC1 699/4885 |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | JUN, CHUK, RELA | CRBN 890/4885DDB1 1148/4885NPC1 2289/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | CRBN 299/4885DDB1 373/4885NPC1 2328/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | CRBN 597/4885DDB1 2953/4885NPC1 1180/4885 |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | CRBN 2615/4885DDB1 585/4885NPC1 1743/4885 |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CRBN 2018/4885DDB1 3802/4885NPC1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.